Malaria Surveillance — United States, 2013

MMWR Surveillance Summaries

Volumn 65, Issue 2, 2016, Pages 1-22

  Cullen, Karen A ^a   Mace, Kimberly E ^a   Arguin, Paul M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; CHILD; DRUG RESISTANCE; FEMALE; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INFANT; ISOLATION AND PURIFICATION; MALARIA; MALE; MIDDLE AGED; NEWBORN; PLASMODIUM; PREGNANCY; PRESCHOOL CHILD; SEASON; SEVERITY OF ILLNESS INDEX; SOLDIER; STATISTICS AND NUMERICAL DATA; TRAVEL; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; BIOMARKERS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALARIA; MALE; MIDDLE AGED; MILITARY PERSONNEL; PLASMODIUM; POPULATION SURVEILLANCE; PREGNANCY; SEASONS; SEVERITY OF ILLNESS INDEX; TRAVEL; UNITED STATES; YOUNG ADULT;

EID: 84977441322     PISSN: 15460738     EISSN: 15458636     Source Type: Journal    
DOI: 10.15585/MMWR.SS6502A1     Document Type: Article

References (60)

1. 1. World Health Organization. World malaria report 2014. Geneva, Switzerland: WHO Press; 2014.
2. 2. World Health Organization. World malaria report 2013. Geneva, Switzerland: WHO Press; 2013.
3. 3. Pan American Health Organization. Report for registration of malaria eradication from United States of America. Washington, DC: Pan American Health Organization; 1969.
4. 4. Andrews JM, Quinby GE, Langmuir AD. Malaria eradication in the United States. Am J Public Health Nations Health 1950;40:1405-11.
5. 5. Mckay T, Bianco T, Rhodes L, Barnett S. Prevalence of Dirofilaria immitis (Nematoda: Filarioidea) in mosquitoes from northeast Arkansas, the United States. J Med Entomol 2013;50:871-8.
6. 6. Cullen KA, Arguin PM. Malaria surveillance—United States, 2011. MMWR Surveill Summ 2013;62(No. SS-5).
7. 7. CDC. Local transmission of Plasmodium vivax malaria—Palm Beach County, Florida, 2003. MMWR Morb Mortal Wkly Rep 2003;52:908-11.
8. 8. Leder K, Black J, O'Brien D, et al. Malaria in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis 2004;39:1104-12.
9. 9. CDC. National notifiable disease surveillance system. Atlanta, GA: US Department of Health and Human Services, CDC; 2012. http://wwwn. cdc.gov/nndss/default.aspx
10. 10. Council of State and Territorial Epidemiologists. Public health reporting and national notification for malaria. Atlanta, GA; 2009. http://c.ymcdn. com/sites/www.cste.org/resource/resmgr/PS/09-ID-47.pdf
11. 11. World Health Organization. Terminology of malaria and of malaria eradication: report of a drafting committee. Geneva, Switzerland: World Health Organization; 1963.
12. 12. World Health Organization. Management of severe malaria: a practical handbook. Third ed. Geneva, Switzerland: WHO Press; 2012.
13. 13. Mali S, Tan KR, Arguin PM. Malaria surveillance—United States, 2009. MMWR Surveill Summ 2011;60(No. SS-3).
14. 14. CDC. Guidance for malaria diagnosis in patients suspected of Ebola infection in the United States. Atlanta, GA: US Department of Health and Human Services; CDC, 2014. http://www.cdc.gov/malaria/ new_info/2014/malaria_ebola.htm
15. 15. BinaxNOW Malaria [package insert]. Scarborough, Maine: Inverness Medical Professional Diagnostics; 2007.
16. 16. CDC. Malaria rapid diagnostic test. MMWR Morb Mortal Wkly Rep 2007;56:686.
17. 17. Bacon DJ, McCollum AM, Griffing SM, et al. Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrob Agents Chemother 2009;53:2042-51.
18. 18. Korsinczky M, Chen N, Kotecka B, et al. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000;44:2100-8.
19. 19. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004;364:438-47.
20. 20. Takala-Harrison S, Clark TG, Jacob CG, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proceedings of the National Academy of Sciences 2012;110(240-5).
21. 21. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014;505:50-5.
22. 22. Talundzic E, Okoth SA, Congpuong K, et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog 2015;11:e1004789.
23. 23. CDC. Malaria surveillance—United States, 2010. MMWR Surveill Summ 2012;61(No. SS-2).
24. 24. CDC. Malaria surveillance—United States, 2012. MMWR Surveill Summ 2014;66(No. SS-12).
25. 25. Mali S, Steele S, Slustker L, Arguin PM. Malaria surveillance—United States, 2008. MMWR Surveill Summ 2010;59(No. SS-7).
26. 26. World Tourism Organization. UNWTO Tourism Highlights, 2013 Edition. Madrid: UNWTO Publications; 2013. http://www.e-unwto. org/content/q27534/fulltext.pdf
27. 27. Armed Forces Health Surveillance Center (AFHSC). Update: malaria, US Armed Forces, 2012. MSMR 2013:2-5, discussion 5.
28. 28. CDC. Guidelines for treatment of malaria in the United States. July 1, 2013. Atlanta, GA: US Department of Health and Human Services, CDC; 2012.
29. 29. Plucinski MM, Huber CS, Akinyi S, et al. Novel mutation in cytochrome b of Plasmodium falciparum in one of two atovaquone-proguanil treatment failures in travelers returning from same site in Nigeria. Open Forum Infect Dis 2014;1:ofu059.
30. 30. Dobson M. The history of malaria in England. Wellcome Trust; 1999. http://malaria.wellcome.ac.uk/doc_wtd023991.html
31. 31. Public Health England. Malaria imported into the United Kingdom in 2013: implications for those advising travellers. London, England. 2014. https://www.gov.uk/government/uploads/system/uploads/ attachment_data/file/326927/hpr1614.pdf
32. 32. Baggett HC, Graham S, Kozarsky PE, et al. Pretravel health preparation among US residents traveling to India to VFRs: importance of ethnicity in defining VFRs. J Travel Med 2009;16:112-8.
33. 33. Balaban V, Warnock E, Ramana Dhara V, et al. Health risks, travel preparation, and illness among public health professionals during international travel. Travel Med Infect Dis 2014;12:349-54.
34. 34. Landman KZ, Tan KR, Arguin PM. Knowledge, attitudes, and practices regarding antimalarial chemoprophylaxis in U.S. Peace Corps Volunteers—Africa, 2013. MMWR Morb Mortal Wkly Rep 2014;63:516-7.
35. 35. Selent M, de Rochars VMB, Stanek D, et al. Malaria prevention knowledge, attitudes, and practices (KAP) among international flying pilots and flight attendants of a US commercial airline. J Travel Med 2012;19:366-72.
36. 36. Diara M, Nowosiwsky A, Harmen S, Burke N, Alilio M. Enabling factors for improved malaria chemoprophylaxis compliance. Am J Trop Med Hyg 2012;87:960-1.
37. 37. Council of State and Territorial Epidemiologists. Public health reporting and national notification for malaria. Atlanta, GA. http://c.ymcdn.com/ sites/www.cste.org/resource/resmgr/PS/13-ID-08.pdf
38. 38. Pan American Health Organization. Status of malaria eradication in the Americas, 18th report. PAHO CSP 18/7. Washington, DC: Pan American Health Organization; 1970. http://new.paho.org/hq/index. php?lang=en
39. 39. Agarwal A, McMorrow M, Arguin PM. The increase of imported malaria acquired in Haiti among US travelers in 2010. Am J Trop Med Hyg 2012;86:9-10.
40. 40. Townes D, Existe A, Boncy J, et al. Malaria survey in post-earthquake Haiti—2010. Am J Trop Med Hyg 2012;86:29-31.
41. 41. CDC. CDC health information for international travel 2012. Chapter: Immigrants returning home to visit friends and relatives (VFRs) by Jay Keystone. New York: Oxford University Press; 2012. 547-51.
42. 42. Londono BL, Eisele TP, Keating J, et al. Chloroquine-resistant haplotype Plasmodium falciparum parasites, Haiti. Emerg Infect Dis 2009;15:735-40.
43. 43. Londono-Renteria B, Eisele TP, Keating J, Bennett A, Krogstad DJ. Genetic diversity in the merozoite surface protein 1 and 2 genes of Plasmodium falciparum from the Artibonite Valley of Haiti. Acta Trop 2012;121:6-12.
44. 44. The Global Fund. Ten countries rally to eliminate malaria in Central America and the Caribbean. 2013. Geneva, Switzerland. http://www. theglobalfund.org/en/mediacenter/newsreleases/2013-06-28_Ten_ Countries_Rally_to_Eliminate_Malaria_in_Central_America_and_ the_Caribbean/
45. 45. Danis K, Baka A, Lenglet A, et al. Autochthonous Plasmodium vivax malaria in Greece, 2011. Euro Surveill 2011;16:1-5.
46. 46. Vakali A, Patsoula E, Spanakos G, et al. Malaria in Greece, 1975 to 2010. Euro Surveill 2012;17:20322.
47. 47. Hellenic Center for Disease Control and Prevention. Epidemiological surveillance report on malaria in Greece, up to 11/16/2013. http://www. keelpno.gr
48. 48. Hellenic Center for Disease Control and Prevention. Epidemiological surveillance report on malaria in Greece, 2014. http://www.keelpno.gr
49. 49. Armed Forces Health Surveillance Center (AFHSC). Update: malaria, US armed forces, 2013. MSMR 2014;21:4-7.
50. 50. Armed Forces Health Surveillance Center. Surveillance snapshot: Selfreported malaria prophylaxis compliance among US service members with diagnosed malaria, 2008-2013. Medical Surveillance Monthly Report 2014;21:15.
51. 51. Brisson M, Brisson P. Compliance with antimalaria chemoprophylaxis in a combat zone. Am J Trop Med Hyg 2012;86:587-90.
52. 52. Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA 2007;297:2264-77.
53. 53. CDC. Primaquine shortage. 2011. http://www.cdc.gov/malaria/ new_info/2011/primaquine.html
54. 54. CDC. Primaquine now available. 2012. http://www.cdc.gov/malaria/ new_info/2012/primaquine.html
55. 55. Filler S, Causer LM, Newman RD, et al. Malaria surveillance—United States, 2001. MMWR Surveill Summ 2003;52(No. SS-5).
56. 56. CDC. Malaria diagnosis & treatment in the United States. 2012. http:// www.cdc.gov/malaria/diagnosis_treatment/index.html
57. 57. CDC. Malaria diagnosis (United States). Atlanta, GA: US Department of Health and Human Services, CDC; 2012. http://www.cdc.gov/malaria/ diagnosis_treatment/diagnosis.html
58. 58. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med 2005; 352:1565-77.
59. 59. Abanyie FA, Arguin PM, Gutman J. State of malaria diagnostic testing at clinical laboratories in the United States, 2010: a nationwide survey. Malar J 2011;10:340.
60. 60. CDC. New medication for severe malaria available under an investigational new drug protocol. MMWR Morb Mortal Wkly Rep 2007;56:769-73.